Clinical Trial Update: Glibentek in Patients With Neonatal Diabetes Secondary to Mutations in K+-ATP Channels [Phase 3]

View source ↗

Summary

Phase 3 trial of Glibentek (glibenclamide) in neonatal diabetes caused by KATP channel mutations has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Abcc8-related Neonatal Diabetes Mellitus
• Kcnj11-related Neonatal Diabetes Mellitus
• Neonatal Diabetes Mellitus

Drugs mentioned

• Glibentek (glibenclamide)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Neonatal Diabetes Secondary to Mutation in the Potassium Channel | Phase 3 | Status: COMPLETED